Proteolysis targeting chimeras (PROTACs) are small molecules capable of targeting disease-relevant proteins for degradation by the ubiquitin-proteasome pathway. The ability to target and destroy a specific protein-of-interest (POI) have made protein degrader molecules promising candidates for developing novel anticancer therapeutics. In this webinar brought to you by BPS Bioscience, Amar Natarajan and Guangrong Zheng will discuss the development and applications of PROTACs for cancer therapy.

Topics to be covered

• PROTACs targeting hepatocyte growth factor receptor mutants
• PROTACs to improve tissue selectivity

Speakers